breast cancer - HR positive | |
la/mBC - HR positive - L2 - all population | |
phosphoinositide 3-kinase (PI3K) inhibitor | |
buparlisib based treatment | |
buparlisib plus fulvestrant | BELLE-2 ... |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -